About Us

Bringing together decades of medical, scientific, and business experience in the drug development and concussion research fields.

Oxeia Biopharmaceuticals is a clinical-stage biotech company developing new, innovative therapeutics for mild traumatic brain injury (mTBI), known as concussion, and related neuro-metabolic dysfunction. The company has a drug, OXE103, that successfully completed a pilot Phase 2a clinical trial in the fall of 2022.  The study showed robust treatment effect across study endpoints. The endpoints were a reduction in symptom burden and improvement in quality of life. The OXE103 responder rate was 85% vs. a baseline of 33%.

To date there are few other studies aimed at treating these patients and no FDA-approved treatment.

The U.S. Centers for Disease Control and Prevention estimates that just under three million concussion cases visit U.S. emergency rooms annually. Other studies put the number much higher at five million, with as many as 2.4 million of these with mTBI. The numbers go even higher with additional studies suggesting that as many as 50 percent of concussions go unreported.

Concussions can result in a serious, long-lasting impact on daily life.  Concussion symptoms include chronic headaches, depression, problems with thinking and memory, vision and balance issues and sleep disorders. Research over the last two decades has increasingly linked concussions to neurodegenerative conditions including dementia, Alzheimer’s disease and chronic traumatic encephalopathy (CTE). No longer considered as a passing consequence treated with rest and rehabilitation, individuals suffering from concussions need effective therapeutic solutions.

Oxeia’s leadership team with deep medical, scientific and business experience brings together the right combination for effective drug development and commercialization.